Abstract:Current genetic tools designed to target macrophages in vivo often target cells from all myeloid lineages. Therefore, we sought to generate a novel transgenic mouse which has a tamoxifen inducible Cre-recombinase under the control of the human CD68 promoter (hCD68-CreERT2). To test the efficiency and specificity of the of Cre-recombinase activity we crossed the hCD68-CreERT2 mice with a loxP-flanked STOP cassette red fluorescent protein variant (tdTomato) mouse. We established that orally dosing mice with 2 mg of tamoxifen for 5 consecutive days followed by a 5-day induction period resulted in robust expression of tdTomato in CD11b + F4/80 + tissue resident macrophages. Using this induction protocol, we demonstrated tdTomato expression within peritoneal, liver and spleen macrophages and blood Ly6C low monocytes. Importantly there was limited or no inducible tdTomato expression within other myeloid cells (neutrophils, monocytes, dendritic cells and eosinophils), T cells (CD4 + and CD8 + ) and B cells (CD19 + ). We also demonstrated that the level of tdTomato expression can be used as a marker to identify different populations of peritoneal and liver macrophages. We next assessed the longevity of tdTomato expression in peritoneal macrophages, liver and splenic macrophages and demonstrated high levels of tdTomato expression as long as 6 weeks after the last tamoxifen dose. Importantly, hCD68-CreERT2 expression is more restricted than that of LysM-Cre which has significant expression in major myeloid cell types (monocytes and neutrophils). To demonstrate the utility of this novel macrophage-specific Cre driver line we demonstrated tdTomato expression in recruited CD11b + CD64 + F4/80 + monocyte-derived macrophages within the atherosclerotic lesions of AAV8-mPCSK9 treated mice, with limited expression in recruited neutrophils. In developing this new hCD68-CreERT2 mouse we have a tool that allows us to target tissue resident macrophages, with the advantage of not targeting other myeloid cells namely neutrophils and inflammatory monocytes.

Transgenic Targeting of Fcrls Creates a Highly Efficient Constitutively Active Microglia Cre Line with Differentiated Specificity

A Human CD68 Promoter-Driven Inducible Cre-Recombinase Mouse Line Allows Specific Targeting of Tissue Resident Macrophages

Transgenic mice for conditional gene manipulation in astroglial cells

Promoter Specificity and Efficacy in Conditional and Inducible Transgenic Targeting of Lung Macrophages

Characterization of transgenic mouse lines for selectively targeting satellite glial cells and macrophages in dorsal root ganglia

An inducible genetic tool to track and manipulate specific microglial states reveals their plasticity and roles in remyelination

Generation of an inducible destabilized-domain Cre mouse line to target disease associated microglia

Identifying the variables that drive tamoxifen‐independent CreERT2 recombination: Implications for microglial fate mapping and gene deletions

A Powerful Transgenic Tool for Fate Mapping and Functional Analysis of Newly Generated Neurons

Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia

A new recombinase mouse line to target intrinsically photosensitive retinal ganglion cells (ipRGCs)

Engineering an inhibitor-resistant human CSF1R variant for microglia replacement

Conditional gene targeting in mouse high endothelial venules

Targeting Corticotropin-Releasing Hormone Receptor Type 1 (CRHR1) Neurons: Validating the Specificity of a Novel Transgenic Crhr1-FlpO Mouse

The generation and characterization of novel Col1a1FRT-Cre-ER-T2-FRT and Col1a1FRT-STOP-FRT-Cre-ER-T2 mice for sequential mutagenesis

Evaluating Tissue-Specific Recombination in a Pdgfrα-CreERT2 Transgenic Mouse Line

A novel Tmem119-tdTomato reporter mouse model for studying microglia in the central nervous system

Efficient Strategies for Microglia Replacement in the Central Nervous System (vol 32, 108041-14.E1, 2020)

Protocol for brain-wide or region-specific microglia depletion and repopulation in adult mice

Directed Differentiation of Human Pluripotent Stem Cells to Microglia

Chemogenetic manipulation of CX3CR1 + cells transiently induces hypolocomotion independent of microglia